R&D channel feed

Ku­ra, Ky­owa say Phase 1 up­date sup­ports menin in­hibitor com­bos 

4 weeks ago

Schrödinger says ear­ly MALT1 da­ta could lay 'great foun­da­tion' for com­bos

4 weeks ago

Ex­clu­sive: Organoid start­up rais­es $21M to test drugs and vac­cines in hu­man lymph nodes-in-a-dish

4 weeks ago
Startups

House ap­pro­pri­a­tors call for FDA tweaks on ac­cel­er­at­ed ap­provals, biosim­i­lars

4 weeks ago
FDA+

Watch Post-Hoc Live: What hap­pens when AI thinks in ways we can’t un­der­stand?

4 weeks ago
Editor's note
AI

Ca­balet­ta Bio shares CAR-T re­sults in three au­toim­mune con­di­tions

4 weeks ago

Vaxart shares surge on norovirus vac­cine da­ta as it seeks fund­ing for new tri­als

4 weeks ago

BMS’ Rayze­Bio inks ra­dio­phar­ma deal in prostate can­cer for $350M up­front

4 weeks ago
Deals

Ar­genx says its drug Vyv­gart looks promis­ing in two more au­toim­mune dis­eases

4 weeks ago
Pharma

FDA’s Makary says he wasn’t part of de­ci­sion to gut ACIP, de­fers pos­si­ble VRB­PAC changes to Prasad

5 weeks ago
Pharma
FDA+

FDA places hold on Gilead­'s stud­ies of HIV treat­ment pill com­bo

5 weeks ago
FDA+

Ex­clu­sive: Re­boot­ing dead hu­man brains, a biotech start­up seeks to rein­vent ear­ly drug test­ing work

5 weeks ago
In Focus

Up­dat­ed: Mer­ck wins FDA ap­proval for RSV an­ti­body drug, mak­ing a hot mar­ket more com­pet­i­tive

5 weeks ago
Pharma
FDA+

Fed­er­al­ly-fund­ed can­cer re­search comes to a per­ilous cross­roads

5 weeks ago
Bioregnum

Mer­ck says its oral PC­SK9 in­hibitor ‘sig­nif­i­cant­ly’ cut cho­les­terol in two Phase 3 tri­als

5 weeks ago

NewAms­ter­dam's ex­per­i­men­tal cho­les­terol drug re­duces pres­ence of Alzheimer's bio­mark­er

5 weeks ago

Met­sera shares ear­ly da­ta on an­ti-obe­si­ty amylin can­di­date

5 weeks ago
Startups

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

Last month

Ot­su­ka spells out Phase 3 win in rare kid­ney dis­ease, Ve­ra’s stock takes a hit

Last month

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

Last month
Pharma

Cor­cept plots fu­ture for ALS drug that flunked Phase 2, cit­ing sur­vival analy­sis

Last month

Re­genxbio says Duchenne gene ther­a­py im­proved mo­tor skills in five pa­tients

Last month
Cell/Gene Tx

Ex­clu­sive: Af­ter cut­ting most staff, Cas­ma eyes path to clin­ic with its first au­tophagy-boost­ing drug

Last month
Pharma

Sagimet's stock ris­es af­ter Chi­na part­ner re­ports pos­i­tive Phase 3 da­ta in ac­ne

Last month
China
First page Previous page 1234567 Next page Last page
A service from the Financial Times